TORONTO, ON / ACCESS Newswire / September 9, 2025 / Helix BioPharma Corp. (TSX:HBP)(OTC:HBPCF)(FRANKFURT:HBP0) ("Helix" or the "Company"), a clinical-stage…
SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage…
New preclinical findings highlight Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene - often called…
NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy…
HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated…
HORGEN, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of…
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September…
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed…
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the…
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone…